The Use of Fluoroproline in MUC1 Antigen Enables Efficient Detection of Antibodies in Patients with Prostate Cancer.
暂无分享,去创建一个
S. Nishimura | G. Bernardes | J. L. Asensio | R. Hurtado-Guerrero | Inês S Albuquerque | H. Hinou | J. Castro-López | F. García-Martín | I. Compañón | F. Corzana | V. J. Somovilla | A. Avenoza | J. H. Busto | J. M. Peregrina | N. Martínez-Sáez | J. Jiménez‐Barbero | I. A. Bermejo | R. Hurtado‐Guerrero | Iris A. Bermejo
[1] M. Rabassa,et al. MUC1 expression and anti-MUC1 serum immune response in head and neck squamous cell carcinoma (HNSCC): a multivariate analysis , 2006, BMC Cancer.
[2] M. Wolfert,et al. Adaptive immune activation: glycosylation does matter. , 2013, Nature chemical biology.
[3] H. Brenner,et al. Blood autoantibodies against tumor-associated antigens as biomarkers in early detection of colorectal cancer. , 2014, Cancer letters.
[4] S. Nishimura,et al. A straightforward protocol for the preparation of high performance microarray displaying synthetic MUC1 glycopeptides. , 2014, Biochimica et biophysica acta.
[5] J. Taylor‐Papadimitriou,et al. Mucins and Cancer , 2013 .
[6] S. Danishefsky,et al. A vision for vaccines built from fully synthetic tumor-associated antigens: from the laboratory to the clinic. , 2013, Journal of the American Chemical Society.
[7] G. Boons,et al. Immunotherapy for cancer: synthetic carbohydrate-based vaccines. , 2009, Chemical communications.
[8] Qureshi,et al. A cancer therapeutic vaccine based on clustered Tn-antigen mimetics induces strong antibody-mediated protective immunity. , 2014, Angewandte Chemie.
[9] J. Jiménez-Barbero,et al. Carbohydrate-aromatic interactions. , 2013, Accounts of chemical research.
[10] Pauline M Rudd,et al. Glycans as cancer biomarkers. , 2012, Biochimica et biophysica acta.
[11] Michael A. Hollingsworth,et al. Mucins in cancer: protection and control of the cell surface , 2004, Nature Reviews Cancer.
[12] J. Amani,et al. Designing a recombinant chimeric construct contain MUC1 and HER2 extracellular domain for prediagnostic breast cancer , 2014, Tumor Biology.
[13] Kohzoh Imai,et al. Circulating anti‐MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer , 2003, International journal of cancer.
[14] G. Jiménez‐Osés,et al. A thorough experimental study of CH/π interactions in water: quantitative structure–stability relationships for carbohydrate/aromatic complexes , 2015, Chemical science.
[15] Yan Tang,et al. Binding of circulating anti-MUC1 antibody and serum MUC1 antigen in stage IV breast cancer. , 2017, Molecular medicine reports.
[16] D. Case,et al. The Dependence of Carbohydrate-Aromatic Interaction Strengths on the Structure of the Carbohydrate. , 2016, Journal of the American Chemical Society.
[17] G. Bernardes,et al. Deciphering the Non-Equivalence of Serine and Threonine O-Glycosylation Points: Implications for Molecular Recognition of the Tn Antigen by an anti-MUC1 Antibody** , 2015, Angewandte Chemie.
[18] Jin-liang Kong,et al. Serum tumor-associated autoantibodies as diagnostic biomarkers for lung cancer: A systematic review and meta-analysis , 2017, PloS one.
[19] S. Nishimura,et al. The Quest for Anticancer Vaccines: Deciphering the Fine-Epitope Specificity of Cancer-Related Monoclonal Antibodies by Combining Microarray Screening and Saturation Transfer Difference NMR. , 2015, Journal of the American Chemical Society.
[20] Li Wang,et al. Detection of Circulating Anti-Mucin 1 (MUC1) Antibodies in Breast Tumor Patients by Indirect Enzyme-Linked Immunosorbent Assay Using a Recombinant MUC1 Protein Containing Six Tandem Repeats and Expressed in Escherichia coli , 2010, Clinical and Vaccine Immunology.
[21] P. V. van Diest,et al. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] U. Karsten,et al. Binding patterns of DTR-specific antibodies reveal a glycosylation-conditioned tumor-specific epitope of the epithelial mucin (MUC1). , 2004, Glycobiology.
[23] C. Lebrilla,et al. Glycans and glycoproteins as specific biomarkers for cancer , 2016, Analytical and Bioanalytical Chemistry.
[24] Timothy Gallagher,et al. Carbohydrate–Aromatic Interactions in Proteins , 2015, Journal of the American Chemical Society.
[25] H. Kunz,et al. The development of synthetic antitumour vaccines from mucin glycopeptide antigens. , 2013, Chemical Society reviews.
[26] Sylvain Julien,et al. Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis , 2011, Breast Cancer Research.
[27] D. Truhlar,et al. The M06 suite of density functionals for main group thermochemistry, thermochemical kinetics, noncovalent interactions, excited states, and transition elements: two new functionals and systematic testing of four M06-class functionals and 12 other functionals , 2008 .
[28] R. Woolson,et al. Upregulated expression of complement inhibitory proteins on bladder cancer cells and anti‐MUC1 antibody immune selection , 2008, International journal of cancer.
[29] M. Wolfert,et al. Mucin architecture behind the immune response: design, evaluation and conformational analysis of an antitumor vaccine derived from an unnatural MUC1 fragment† †Electronic supplementary information (ESI) available: Characterization of the new compounds, biological assays and MD simulations. See DOI: , 2015, Chemical science.
[30] M. Sternberg,et al. Crystal structure at 1.95 A resolution of the breast tumour-specific antibody SM3 complexed with its peptide epitope reveals novel hypervariable loop recognition. , 1998, Journal of molecular biology.
[31] D. Kufe,et al. Mucins in cancer: function, prognosis and therapy , 2009, Nature Reviews Cancer.